Synchron Inc., a competitor to Elon Musk's Neuralink brain implant venture, is gearing up to recruit participants for a large-scale clinical trial necessary for its device's commercial approval. The company plans to launch an online registry to enrol interested patients, has garnered interest from over 120 clinical trial centres, and aims to aid local physicians in engaging with motor-impaired patients to avoid bottlenecks.
This New York-based company, ahead of Neuralink in testing its brain implant, received preliminary U.S. authorization in 2021, implanting devices in six patients without serious adverse effects reported. Synchron is analysing U.S. data to prepare for a larger study, seeking FDA authorization while targeting paralyzed patients due to ALS, stroke, and multiple sclerosis.
Collaborating with renowned institutions like Mount Sinai, University at Buffalo Neurosurgery, and UPMC, Synchron hopes to include these centres in the expanded trial.
Their technology, which uses veins near the brain's motor cortex for implantation, competes in the brain-computer interface (BCI) devices sector, with investors including Jeff Bezos and Bill Gates. Synchron aims to screen stroke patients for implant suitability following FDA guidance and plans to broaden the market beyond quadriplegics. Despite challenges in stroke patient testing, Synchron's technology has shown promise, outperforming non-invasive devices in typing speeds. Details from their ongoing U.S. trial remain undisclosed, while recent acquisitions indicate a push for manufacturing enhancement. Previous reports suggest Elon Musk has shown interest in investing in Synchron.
Click here to read the original news story.